Kaposi sarcoma associated with rituximab-based cytotoxic therapy
dc.authorid | TOPRAK, SERHAT/0000-0003-4136-0523 | |
dc.authorid | Yaşar, Hatime Arzu/0000-0002-0545-1383 | |
dc.authorid | Alkan, Ali/0000-0002-8253-5046; | |
dc.authorwosid | TOPRAK, SERHAT/AAD-7854-2021 | |
dc.authorwosid | Yaşar, Hatime Arzu/HGC-5631-2022 | |
dc.authorwosid | Alkan, Ali/P-3554-2019 | |
dc.authorwosid | TOPRAK, Serhat/ABI-5367-2020 | |
dc.contributor.author | Alkan, Ali | |
dc.contributor.author | Yasar, Arzu | |
dc.contributor.author | Toprak, Serhat | |
dc.date.accessioned | 2024-08-04T20:45:50Z | |
dc.date.available | 2024-08-04T20:45:50Z | |
dc.date.issued | 2020 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy. | en_US |
dc.identifier.doi | 10.1177/1078155219835592 | |
dc.identifier.endpage | 223 | en_US |
dc.identifier.issn | 1078-1552 | |
dc.identifier.issn | 1477-092X | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 30854926 | en_US |
dc.identifier.scopus | 2-s2.0-85062793902 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 220 | en_US |
dc.identifier.uri | https://doi.org/10.1177/1078155219835592 | |
dc.identifier.uri | https://hdl.handle.net/11616/98721 | |
dc.identifier.volume | 26 | en_US |
dc.identifier.wos | WOS:000501268400028 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications Ltd | en_US |
dc.relation.ispartof | Journal of Oncology Pharmacy Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Rituximab | en_US |
dc.subject | Kaposi sarcoma | en_US |
dc.subject | lymphoma | en_US |
dc.subject | HHV-8 | en_US |
dc.title | Kaposi sarcoma associated with rituximab-based cytotoxic therapy | en_US |
dc.type | Article | en_US |